Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of KBL697 in Healthy Volunteers
NCT04056130Phase 1Completed
- Sponsor
- KoBioLabs
- Start
- Oct 2019
- Primary completion
- Dec 2019
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lactobacillus gasseri KBL697 in atopic dermatitis (AD) (4 cohorts), sponsored by KoBioLabs. Primary endpoints: Adverse Events/Serious Adverse Events, Vital Sign and 4 more. Started Oct 2019; status: completed.
02
Drugs
Lactobacillus gasseri KBL697
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04056130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04056130.